Lymphoid leukemias and lymphomas originate from the malignant transformation and clonal proliferation of one or a small number of B- or T-cells. Since each B- or T-cell expresses distinct receptors on its surface, the unique B-cell receptor (BCR) or T-cell receptor (TCR) sequences can serve as an identifier tag that can be used to detect and measure potential malignant clones of interest at low frequencies. In addition, as research continues in the field of lymphoid malignancies, the list of known mutations and relevant genes is increasing as well. High-throughput sequencing via NGS is increasingly being adopted for lymphoid malignancy researach due to its advantages over other more traditional approaches by offering ultrahigh sensitivity, lower limits of detection (LOD), and greater flexibility to multiplex.
The Oncomine Lymphoma Panel is one of our new tumor specific panels: small curated panels with verified performance that complement the Oncomine menu of assays. The lymphoma panel specifically contains 25 key genes associated with all major B-cell lymphomas, including DLBCL, follicular lymphoma, mantle cell lymphoma, and marginal zone lymphomas. Tailor the panel content to fit your specific needs with additional genes from the inventory on Ion AmpliSeqTM Designer. This panel provides robust performance with as little as 10 ng of input and comes with an end-to-end, clinical research-grade workflow including straightforward, customizable report that summarizes the findings.
The Ion Torrent Oncomine BCR IGH assays are a pair of powerful and sensitive NGS assays that make it easier to assess the BCR repertoire and detect rare clones in hemato-oncology research. The long-read (LR) assay is ideal for clonality assessment and accurate quantification of somatic hypermutation (SHM). In addition, this assay offers unique features such as the identification of isotypes in the B-cell population. These exclusive features provide valuable information that may aid in the interpretation of challenging samples that have a polyclonal background or that continue to undergo SHM.
The short-read (SR) assay is designed for clonality assessment and to detect the presence of rare B-cell clones with high sensitivity and ultralow LOD (down to 10-6). Compatible with both DNA and RNA, the assay combines superior informatics with an end-to-end, clinical research-grade workflow that makes it easy to compare the frequency of potential malignant clones of interest across samples.
The Oncomine TCR Beta-SR Assay specifically interrogates the CDR3 region of the T-cell receptor (TCR) beta chain. In hemato-oncology research, this short-read sequencing assay enables detection of low frequency T-cell clones in peripheral blood, with a LOD of 10-4 to 10-5. With low sample-input requirements, this assay offers a two-day turnaround time complete with superior informatics for accurate clonality and CDR3 TCR beta chain sequence assessment without interference from primer bias.
If you are interested in learning more about Oncomine solutions for lymphoid malignancy research, a local representative can contact you to set up a demonstration or discuss pricing options.
*For Research Use Only. Not for use in diagnostic procedures.